
ER positive, HER2 negative Breast Cancer - Pipeline Insight, 2024
Description
ER positive, HER2 negative Breast Cancer - Pipeline Insight, 2024
DelveInsight’s, “ER+/ HER2 -ve Breast Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ER+/ HER2 -ve Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
ER+/ HER2 -ve Breast Cancer: Overview
Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. Most breast cancers express the estrogen receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. The backbone of their systemic therapy consists of hormonal therapies that block the function of ER through various mechanisms. These include blockade of the receptor itself in breast cancer cells, blockade of the production of its major ligand, estradiol, or degradation of the receptor. However, a subset of ER+/HER2− breast cancers, mostly corresponding to the genomic luminal B genotype, are resistant to hormonal manipulations from the outset of therapies.
""ER+/ HER2 -ve Breast Cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ER+/ HER2 -ve Breast Cancer pipeline landscape is provided which includes the disease overview and ER+/ HER2 -ve Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth ER+/ HER2 -ve Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ER+/ HER2 -ve Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence ER+/ HER2 -ve Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve ER+/ HER2 -ve Breast Cancer.
This segment of the ER+/ HER2 -ve Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ER+/ HER2 -ve Breast Cancer Emerging Drugs
- H3B-6545: Eisai
- Rintodestrant (G1T48): G1 Therapeutics
- GDC-9545: Genetech/ La Roche
Further product details are provided in the report……..
ER+/ HER2 -ve Breast Cancer: Therapeutic Assessment
This segment of the report provides insights about the different ER+/ HER2 -ve Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in ER+/ HER2 -ve Breast Cancer
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
ER+/ HER2 -ve Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Parenteral
- Intramuscular
- Molecule Type
- Small molecules
- Peptides
- Polymer
- Gene Therapy
- Monoclonal antibodies
- Product Type
ER+/ HER2 -ve Breast Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ER+/ HER2 -ve Breast Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ER+/ HER2 -ve Breast Cancer drugs.
ER+/ HER2 -ve Breast Cancer Report Insights
- ER+/ HER2 -ve Breast Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing ER+/ HER2 -ve Breast Cancer drugs?
- How many ER+/ HER2 -ve Breast Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ER+/ HER2 -ve Breast Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ER+/ HER2 -ve Breast Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ER+/ HER2 -ve Breast Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eisai
- G1 Therapeutics
- Genetech/La Roche
- Sanofi
- AstraZeneca
- H3B-6545
- G1T48
- GDC-9545
- SAR439859
- AZD9833
Table of Contents
40 Pages
- Introduction
- Executive Summary
- ER+/ HER2 -ve Breast Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- ER+/ HER2 -ve Breast Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- ER+/ HER2 -ve Breast Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- ER+/ HER2 -ve Breast Cancer Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Rintodestrant (G1T48): G1 Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- ER+/ HER2 -ve Breast Cancer Key Companies
- ER+/ HER2 -ve Breast Cancer Key Products
- ER+/ HER2 -ve Breast Cancer- Unmet Needs
- ER+/ HER2 -ve Breast Cancer- Market Drivers and Barriers
- ER+/ HER2 -ve Breast Cancer- Future Perspectives and Conclusion
- ER+/ HER2 -ve Breast Cancer Analyst Views
- ER+/ HER2 -ve Breast Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.